Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Amortizatization of Intangibles: 2012-2025

Historic Amortizatization of Intangibles for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $3.1 million.

  • Agios Pharmaceuticals' Amortizatization of Intangibles fell 2.37% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.8 million, marking a year-over-year increase of 27.72%. This contributed to the annual value of $14.5 million for FY2024, which is 35.13% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Amortizatization of Intangibles stood at $3.1 million for Q3 2025, which was up 1.92% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $5.6 million in Q4 2024 and a low of $2.2 million during Q3 2023.
  • Its 3-year average for Amortizatization of Intangibles is $3.1 million, with a median of $3.0 million in 2023.
  • Per our database at Business Quant, Agios Pharmaceuticals' Amortizatization of Intangibles decreased by 11.30% in 2023 and then skyrocketed by 104.00% in 2024.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Amortizatization of Intangibles stood at $2.4 million in 2021, then increased by 6.44% to $2.6 million in 2022, then climbed by 7.41% to $2.8 million in 2023, then spiked by 104.00% to $5.6 million in 2024, then decreased by 2.37% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.1 million for Q2 2025, and $3.0 million during Q1 2025.